Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about GSK’s Nucala® (mepolizumab) receives approval from US FDA
GlaxoSmithKline plc received approval from the US Food and Drug Administration (FDA) for its Biologics License Application (BLA) for Nucala® (mepolizumab) as an add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Nucala is not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.
- Read more about IPC set to become the first WHO Collaborating Centre for Safety of Medicines and Vaccines in South-East Asia
The Indian Pharmacopoeia Commission (IPC) is set to become the first WHO Collaborating Centre for Safety of Medicines and Vaccines in the South-East Asia Region. This was stated by Shri J P Nadda, Union Minister of Health and Family Welfare while addressing the 38th Annual Meeting of Representatives of the National Pharmacovigilance Centres participating in the World Health Organization Programme for International Drug Monitoring, organized by the Indian Pharmacopoeia Commission (IPC) and World Health Organization (WHO).
- Read more about Dr Reddy's Lab receives FDA warning over three facilities
Leading drugmaker Dr Reddy's Laboratories today acknowledged having received a warning letter from the US FDA relating to its three manufacturing plants in Andhra Pradesh and Telangana.
- Read more about NIPERs and Pharma Industries bridged to fulfill academic and industry gap
National Institutes for Pharmaceutical Education and Research (NIPERs) and Pharma Industries signed 17 MoU to bridge gap betwwen academic education and industrial needs. One of the critical factors in building innovation ecosystem and for Drug Discovery is Academia-Industry linkage. Department of Pharmaceuticals (DoP) for the last one year has actively engaged both the NIPERs and the Pharma Industry to build partnership in areas of education, research and development.
- Read more about Omega 3 supplements ineffective in depression
Widely thought to be essential for good health, Omega 3 fatty acid supplements may not be of much help in treating major depressive disorders, suggests new research.
- Read more about Piramal Enterprises Acquires the Baby Care Brand - Little's for the Consumer Products Business
(Business Wire India); Piramal Enterprises’ Consumer Products Division announces the acquisition of the baby-care brand “Little’s”, which includes the entire product range across six categories.
- Read more about Premature ejaculation is not a true illness: Study
Premature ejaculation including female sexual dysfunction should not be classified as an illness, argue researchers, adding that the illness factor may have been constructed by sexual medicine experts under the influence of drug companies.
- Read more about Depression can damage your memory
Once they enter memory, depressive thoughts can linger for long in affected people, and this extended duration may reduce the amount of information that these individuals can remember, suggests new research.

[adsense:336x280:8701650588]
- Read more about Hepatitis A virus likely of animal origin
Like HIV and Ebola, the hepatitis A virus is of likely animal origin, finds a large-scale study looking into the evolutionary origins of the global pathogen.
- Read more about Even 'SAFE' levels of air pollution up heart attack risk
Particulate matter and nitric dioxide emissions from industrial plants or vehicles increase the risk of heart attacks, despite being within 'safe' levels of air pollution, a new study has claimed. The study examined the effect of short term exposure to air pollution on the risk of ST-segment elevation myocardial infarction (STEMI). This type of myocardial infarction (heart attack) has the worst prognosis and is caused by thrombotic occlusion of a coronary artery that damages the heart.